Primary information |
---|
Hemolytik ID | 3252 |
PMID | 23328867 |
YEAR | 2013 |
SEQUENCE | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK |
LENGTH | 32 |
NAME | TfR-lytic hybrid peptide |
C-ter Modification | Free |
N-ter Modification | Free |
Linear/Cyclic | Linear |
Stereochemistry | Mix (Contains both L and D amino acids) |
Modified Residues | None |
FUNCTION | Anticancer |
ACTIVITY | 17% hemolysis at 100μM |
RBCs SOURCE | Mouse |
Secondary information |
---|
Properties | Physico-Chemical details |
STRUCTURE | |
DSSP states | CCBTTBSSSSSCCCTHHHHHHHHHHHHHHHHC |
SMILES | N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]c(C)c1CC)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c(C)c1CC)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O |
External Links |
---|
PDB exact | PDB partial | SP exact | SP partial | TrEMBL exact | TrEMBL partial | IEDB exact | IEDB partial |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
|
Reference Informaiton |
---|
ARTICLE | Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent. |
AUTHORS | Kawamoto M,Kohno M,Horibe T |
JOURNAL | Cancer Chemother Pharmacol. 2013 Mar;71(3):799-807. doi: 10.1007/s00280-013-2074-4. Epub 2013 Jan 18. |